Jeffrey L. Curtis

307 posts

Jeffrey L. Curtis

Jeffrey L. Curtis

@jlcaa_l

Physician-scientist

Ann Arbor, MI Katılım Ekim 2014
95 Takip Edilen79 Takipçiler
Jeffrey L. Curtis retweetledi
MeiLan Han
MeiLan Han@meilan_han·
Thank you Wassim Labaki for nominating me for the @ATSCPAssembly award. I’m the one who is lucky to have you as a mentee! Thanks also to my mentor Fernando Martinez for teaching so well. @MichiganPulmCC
MeiLan Han tweet media
English
1
9
87
6K
Jeffrey L. Curtis
Jeffrey L. Curtis@jlcaa_l·
Congratulations, Francesca Polverino on winning the 2022 ERS MID-CAREER GOLD MEDAL IN COPD Francesca Polverino, MD, PhD, has done major contributions to the field of COPD pathogenesis. At the age of 34, Francesca became a faculty member at Harvard Medica…lnkd.in/gDE9ZR2D
English
0
0
7
0
Jeffrey L. Curtis
Jeffrey L. Curtis@jlcaa_l·
I’m very excited that the VA Ann Arbor Healthcare System has been chosen to join the VA Cooperative Studies Program’s (CSP) network of designated enrollment sites (NODES).  This program will increase our ability to bring cutting-edge clinical research op…lnkd.in/gZdGSdbF
English
0
0
1
0
James Beck, MD, ATSF 🇺🇦
James Beck, MD, ATSF 🇺🇦@JamesBeck_MD·
Dear @atscommunity , tomorrow I will be retiring from @VAECHCS after 31 1/2 years of VA service. It’s been the honor of my career to care for Veterans in PA, CA, MI, and CO. I’ll continue my involvement with @atscommunity including chairing our Task Force on Governance.
Denver, CO 🇺🇸 English
32
7
145
0
Jeffrey L. Curtis retweetledi
ALA Midland States
ALA Midland States@MidlandLung·
Every year, more than 156,000 Americans die from #COPD. It’s important that we better understand this disease and its impact on Americans, so that we can find solutions to save lives. Lung.org/copd-trends
ALA Midland States tweet media
English
0
2
0
0
Frank Sciurba
Frank Sciurba@FrankS1956·
Our group led by @realmdransfield at #Chest2019 and @NEJM showed in #COPD pts, w/o other indication, beta blockers do not prevent exacerbation but increase risk for hospitalization (HR 1.91). Risk/benefit UNKNOWN in COPD pts w cardiovascular indication!?
NEJM@NEJM

In this randomized trial involving patients with moderate or severe #COPD, treatment with the beta-blocker metoprolol did not result in a shorter time until the first COPD exacerbation than placebo. #CHEST2019 nej.md/2P5nANc

English
2
4
15
0